(Corrects paragraph 8 of Dec. 17 story to reflect that the EU regulator reversed its July decision in November to recommend ...

China's medical regulator has approved Eli Lilly's treatment for early Alzheimer's, providing patients with another option ...

Eli Lilly (LLY) stock in focus as China approves its Alzheimer's treatment Kisunla (donanemab). Read more here.

Shares of Biogen Inc. BIIB slid 2.56% to $146.79 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 2.95% to 5,872.16 and Dow ...

China is the fourth major market where Kisunla has been approved after the US, Japan, and GB. It gets the green light there ...

We will explore the elements of innovation ecosystems and offer insights into how entrepreneurs can leverage them for success ...

The Conference Forum is pleased to announce the agenda and keynote speakers for the 13th annual Chief Medical Officer Summit ...

The summary highlights significant activities in the health sector, including Eli Lilly's Alzheimer's treatment approval in ...

China has approved Eli Lillys Kisunla, marking another milestone in global efforts to address Alzheimers disease. The ...

It’s important to connect with loved ones this time of year but when Alzheimer’s is in the mix, it can be extra stressful.

The bipartisan agreement will fund the government through March. It could also reshape the pharmacy supply chain by reforming ...

The Centers for Medicare and Medicaid Services is directing all Medicare Advantage plans to cover Qalsody for treating ...